No Data
No Data
Press Release: Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
New Analyst Forecast: $HRMY Given $48.0 Price Target
UBS Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Cuts Target Price to $48
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Apellis Pharmaceuticals (APLS) and Eton Pharmaceuticals (ETON)
Could The Market Be Wrong About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Its Attractive Financial Prospects?
Harmony Regrets to Announce a Loss of Life Incident at Moab Khotsong Mine on 25 April 2025